Literature DB >> 26616890

Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus.

Claudio Guarneri1, Maria Lentini2, Giovanni Polimeni3, Roberta Giuffrida1, Serafinella P Cannavò1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26616890      PMCID： PMC4799931          DOI： 10.1111/bcp.12837

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  ACE-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and Lupus erythematosus tumidus.

Authors:  Carmelo Schepis; Maria Lentini; Maddalena Siragusa; Dario Batolo
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

2.  Lymphocytic infiltration of the skin Jessner-Kanof after treatment with a hydroquinone-containing bleaching cream.

Authors:  Ulrich M Caroli; Diana Berner; Christiane Schlegel; Gisela Metzler; Martin Röcken; Tilo Biedermann
Journal:  Arch Dermatol       Date:  2006-12

Review 3.  Severe drug-induced dermatoses.

Authors:  Iris Ahronowitz; Lindy Fox
Journal:  Semin Cutan Med Surg       Date:  2014-03

4.  Duloxetine-induced pseudolymphoma with features of lymphocytic infiltration of Jessner-Kanof.

Authors:  Monica Corazza; Alessandro Borghi; Sara Minghetti; Lucia Mantovani; Roberta Gafà; Annarosa Virgili
Journal:  Acta Derm Venereol       Date:  2014-09       Impact factor: 4.437

5.  What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.

Authors:  Marina Talamonti; Marco Galluzzo; Luca Bianchi; Andreea N Boca; Antonio Costanzo; Sergio Chimenti
Journal:  Dermatology       Date:  2014-11-15       Impact factor: 5.366

6.  Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate.

Authors:  S Nolden; C Casper; A Kuhn; H F Petereit
Journal:  Mult Scler       Date:  2005-04       Impact factor: 6.312

7.  Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases.

Authors:  Dan Lipsker; Audrey Mitschler; Edouard Grosshans; Bernard Cribier
Journal:  Dermatology       Date:  2006       Impact factor: 5.366

8.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

9.  Histopathologic findings in lupus erythematosus tumidus: review of 80 patients.

Authors:  Annegret Kuhn; Monika Sonntag; Thomas Ruzicka; Percy Lehmann; Mosaad Megahed
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

10.  Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?

Authors:  Laëtitia Sparsa; Naji Afif; Joëlle Goetz; Christelle Sordet; Emmanuel Chatelus; Dan Lipsker; Jean Sibilia
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631
View more
  6 in total

1.  Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus.

Authors:  Claudio Guarneri; Maria Lentini; Giovanni Polimeni; Roberta Giuffrida; Serafinella P Cannavò
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

Review 2.  A Practical Guide to the Safety and Monitoring of New IBD Therapies.

Authors:  Benjamin Click; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

3.  Lupus erythematosus tumidus: clinical perspectives.

Authors:  Nikolaos Patsinakidis; Ocko Kautz; Bernhard F Gibbs; Ulrike Raap
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-10-01

4.  Secukinumab for psoriasis in a patient with familial Mediterranean fever.

Authors:  Serafinella P Cannavò; Valeria Papaianni; Annunziata Bartolotta; Claudio Guarneri
Journal:  Dermatol Ther       Date:  2019-10-24       Impact factor: 2.851

Review 5.  An update on the management of refractory cutaneous lupus erythematosus.

Authors:  Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni
Journal:  Front Med (Lausanne)       Date:  2022-09-23

Review 6.  Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.

Authors:  Sahil Rawal; Sara Kianian; William Guo; Jocellie Marquez; Marissa Ayasse; Katherine A Siamas; Yoojin Lee; Joann Salvemini
Journal:  Arch Dermatol Res       Date:  2021-06-22       Impact factor: 3.017
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.